慢性肝病患者骨代谢变化的临床意义

为探讨慢性乙型肝炎（下称慢乙肝），乙肝肝硬化（下称肝硬化）与骨代谢的关系，分别对32例慢乙肝，32例肝硬化和31例对照组患者进行了骨钙素（BGP），甲状旁腺激素M（PTHM），血钙，血磷及尺桡骨骨密度（BMD）检测。结果显示，肝硬化组血清BGP水平较肝炎组和对照组明显降低（P＜0．05，＜0．01），血清PTHM水平较肝炎组及对照组升高（P＜0．05，＜0．05），两肝病组血钙水平较对照组明显下降（P均＜0．001），BMD较对照组降低（P＜0．001，＜0．01）；肝硬化组和肝炎组BGP均与BMD呈正相关。提示慢性病毒性肝病可出现调钙激素异常变化，且其骨质疏松随肝病加重而呈加重趋势。     

慢性病毒性肝病钙调节激素与骨密度的关系探讨

探讨慢性病毒性肝病患者骨密度及钙调节激素的变化及其间的相互关系。用NM—300单光子骨密度测量系统检测骨密度，空腹抽血检测钙调节激素：1，25二羟维生素D3[1，25(OH)2D3]、甲状旁腺素M(PTHM)、降钙素(CT)、骨钙素(BGP)。慢性肝炎和肝硬化组尺、桡骨宽度(BM)、骨密度(BMC)、骨矿物质含量(BMD)较对照组均降低，且随肝病的进程而加重；1，25(OH)2D3、BGP降低，PTHM、CT升高；1，25(OH)2D3、BGP与尺桡密度呈正相关，PTHM、CT与尺桡密度无相关。慢性病毒性肝病引起肝性骨病(BHD)在肝炎阶段已开始产生，BHD的发生主要是骨形成减少，而非骨破坏过多，1，25(OH)2D3的降低是其发生、发展的始动因素。     

乙型肝炎肝硬化骨代谢异常的临床研究

目的探讨乙型肝炎肝硬化患者骨代谢异常的发病机制。方法用NM-300单光子骨密度测量系统检测61例乙型肝炎肝硬化患者的骨密度，空腹抽血检测血清钙调节激素：1，25二羟维生素D3[1，25（OH）2D3]、甲状旁腺素（PTH）、降钙素（CT）、骨钙素（BGP），白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、肿瘤坏死因子α（TNF α）、尿骨胶原交联（Corsslaps），并与30名健康者对照。结果肝硬化组尺骨密度、桡骨密度、尺桡密度均较对照组明显降低。肝硬化组血清1，25（OH）2D3、BGP水平较对照组明显降低，其中骨质疏松（OP）组较无骨质疏松（NOP）组降低更明显，尿Crosslaps水平肝硬化组较对照组明显升高，其中OP组较NOP升高更明显。血清1，25（OH）2D3、BGP水平与尺桡密度呈正相关。OP组尿Crosslaps水平与尺桡密度呈负相关，而NOP组尿Crosslaps水平与尺桡密度无相关关系。肝硬化组血清IL-1β、IL-6、TNF α水平较对照组明显升高。血清IL-1β、IL-6、TNF α水平肝硬化OP组较NOP组显著升高。肝硬化组IL-1β、IL-6、TNF α水平与尺桡密度呈负相关，其中OP组较NOP组相关性更明显。结论乙型肝炎肝硬化患者存在着骨形成减少和骨破坏过多两种因素，从而引起肝性骨病，在骨形成减弱的过程中1，25（OH）2D3起了主要作用，在骨吸收增强的过程中IL-1β、IL-6、TNF α起到了重要的作用。     

慢性乙型肝炎、肝硬化患者骨密度的变化及相关分析

慢性乙型肝炎、肝硬化患者由于肝细胞功能损害,出现不同程度的骨代谢异常,通过化验肝功能、胆碱 酯酶(ChE)、凝血酶原活动度(PTA)、血清钙,测量骨密度(BMD),发现慢性乙型肝炎、肝硬化患者骨密度与胆碱酯 酶、凝血酶原活动度正相关,与丙氨酸氨基转移酶(ALT)、胆红素(TBil)无相关性。肝脏储备功能越差,骨代谢异常 越明显,ALT、TBil与骨代谢无关。     

Evaluation of bone mineral density in women with chronic liver diseases during perimenopausal period

Osteoporosis is the most frequently occurring metabolic diseases of bones, observed especially in women after menopause. The goal of the paper was a comparison of bone mineral density (BMD) of health women with that in perimenopausal patients with chronic liver diseases. The study was performed in 47 patients with chronic liver diseases, aged: 37-56 years. Qualification criteria included chronic type B hepatitis, chronic type C hepatitis and cirrhosis of viral aetiology. The control group consisted of 15 healthy, age-matched women. All the women had been examined in order to identify other risk factors of osteoporosis development. RESULTS: The incidence of decreased BMD was statistically higher in the group of patients with chronic hepatic diseases, compared to the group of healthy subjects. No bone fracture was found in any of the examined patients. CONCLUSIONS: Routine densitometric examinations should be performed in all women in perimenopausal age with chronic liver diseases. Results of our studies indicate that in patients with liver diseases, the lowest BMD values are found in the group of patients with cirrhosis or chronic type C hepatitis. These women constitute a large risk group for secondary osteoporosis development.     

Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection

AIM: Previous studies suggest that loss of bone mineral density (BMD) frequently occurs in patients with chronic viral liver disease, presenting with histologically proven liver cirrhosis. However, little is known about the occurrence of bone disease in non-cirrhotic patients with chronic hepatitis B or C. Therefore, it was the aim of this study to evaluate this particular population for BMD and bone turnover markers. METHODS: Biochemical markers of bone turnover and BMD were measured in 43 consecutive patients with HCV (n = 30) or HBV (n = 13) infection without histological evidence for liver cirrhosis. Mean age was 49 years (range 26-77 years). BMD was measured by dual X-ray absorptiometry in the femoral neck (FN) and the lumbar spine (LS) region. In addition, bone metabolism markers were measured. RESULTS: BMD was lowered in 25 (58%) of the patients with chronic hepatitis B or C (FN; 0.76 (0.53-0.99); LS: 0.96 (0.62-1.23) g/cm2). Eight (32%) osteopenic patients were diagnosed with osteoporosis. Bone-specific alkaline phosphatase (P= 0.005) and intact parathyroid hormone (iPTH) (P = 0.001) were significantly elevated in the more advanced stages of fibrosis. Mean T-score value was lower in patients with chronic hepatitis C as compared to patients suffering from chronic hepatitis B; however, the difference was not statistically significant (P= 0.09). CONCLUSION: There was a significantly reduced BMD in non-cirrhotic patients with chronic hepatitis B or C infection. Alterations of bone metabolism already occurred in advanced liver fibrosis without cirrhosis. According to our results, these secondary effects of chronic viral hepatitis should be further investigated.     

Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver

OBJECTIVE: Bone loss frequently appears in the natural history of liver disease. The effects of therapy for osteoporosis associated with cirrhosis of the liver are still controversial. We evaluated the effects of vitamin K2 on osteopenia in women with cirrhosis. METHODS: The subjects were 50 women with cirrhosis who had underlying hepatitis viral infections. Half of the patients were randomly assigned to receive vitamin K2 (menatetrenone). The bone mineral density (BMD) of the lumbar vertebrae was measured by dual-energy X-ray absorptiometry at entry and at 1-yr intervals for 2 yr. RESULTS: The percentages of change from the initial BMD at 1 and 2 yr after initiation of the study were, respectively, +0.1 +/- 2.6% and -0.5 +/- 3.5% for the vitamin K2-treated group and -2.2 +/- 2.4% and -4.6 +/- 3.9% for the control group. The changes in BMD at each timepoint differed significantly between the control and treated groups (p = 0.008 for 1 yr and p = 0.002 for 2 yr). In the vitamin K2-treated group, the ratio of osteocalcin to undercarboxylated osteocalcin in those patients with increases in BMD after 1 yr of treatment was significantly lower than that in patients showing decreases in BMD (p = 0.017). No adverse effects of vitamin K2 were noted. CONCLUSIONS: Vitamin K2 can prevent bone loss and may therefore be useful in the management of bone disease in women with cirrhosis of the liver.     

Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis?

Metabolic bone disease has long been recognized in chronic liver disease, especially cholestatic or alcoholic liver diseases. The aim of the present study was to investigate the prevalence and severity of osteodystrophy in cirrhotic men and the correlation of its incidence with the clinical severity of cirrhosis in an endemic area of post-necrotic hepatitis. We measured serum levels of osteocalcin, 25-hydroxyvitamin D, parathyroid hormone mid-molecule, calcium and testosterone in 74 cirrhotic men (Child-Pugh's classification grade A n= 30, B n= 21 and C n= 23) and 16 healthy controls. Standard X-rays and bone mineral densities of lumbar spine were performed in 30 patients with post-necrotic cirrhosis and 10 healthy controls. Serum levels of osteocalcin, parathyroid hormone and testosterone were significantly lower in patients with cirrhosis than in controls. Changes paralleling an increased severity of cirrhosis were found in the serum levels of 25–hydroxyvitamin D and testosterone, but not in the serum levels of osteocalcin and parathyroid hormone. The lumbar bone mineral density was significantly lower in patients with post-necrotic cirrhosis than in controls (0.97 ± 0.13 vs 1.07±0.12 g/cm², P<0.05) and was correlated with serum 25–hydroxyvitamin D levels (r = 0.467; P<0.005). There was no correlation between the bone mineral density and serum osteocalcin or the clinical severity of cirrhosis. The prevalence of spinal osteoporosis, as defined by a lumbar bone mineral density greater than two standard deviations below the mean value of the controls, was 20% in cirrhotic patients compared with 10% in controls. Two (6.7%) patients (both grade C) had spinal compression fractures compared with none in the control group. In conclusion, serum osteocalcin and lumbar bone mineral density were significantly lower in cirrhotic men than in controls. However, they were not correlated with each other or the clinical severity of cirrhosis.     

Bone mineral density and disorders of mineral metabolism in chronic liver disease

AIM： To estimate the prevalence and identify the risk factors for metabolic bone disease in patients with cirrhosis. METHODS： The study was performed on 72 Indian patients with cirrhosis （63 male, 9 female; aged 〈 50 years）. Etiology of cirrhosis was alcoholism （n = 37）, hepatitis B （n = 25） and hepatitis C （n = 10）. Twenty-three patients belonged to Child class A, while 39 were in class B and 10 in class C. Secondary causes for metabolic bone disease and osteoporosis were ruled out. Sunlight exposure, physical activity and dietary constituents were calculated. Complete metabolic profiles were derived, and bone mineral density （BMD） was measured using dual energy X ray absorptiometry. Low BMD was defined as a Z score below -2. RESULTS： Low BMD was found in 68% of patients. Lumbar spine was the most frequently and severely affected site. Risk factors for low BMD included low physical activity, decreased sunlight exposure, and low lean body mass. Calcium intake was adequate, with unfavorable calcium： protein ratio and calcium： phosphorus ratio. Vitamin D deficiency was highly prevalent （92%）. There was a high incidence of hypogonadism （41%）. Serum estradiol level was elevated significantly in patients with normal BMD. Insulin-like growth factor （IGF） 1 and IGF binding protein 3 levels were below the age-related normal range in both groups. IGF-1 was significantly lower in patients with low BMD. Serum osteocalcin level was low （68%） and urinary deoxypyridinoline to creatinine ratio was high （79%）, which demonstrated low bone formation with high resorption. CONCLUSION： Patients with cirrhosis have low BMD. Contributory factors are reduced physical activity, low lean body mass, vitamin D deficiency and hypogonadism and low IGF-1 level.     

Estimation of portosystemic shunt by transrectally administered 123I-IMP

Portosystemic shunt index was estimated in 7 patients without liver disease and 95 patients with various liver diseases by portal scintigraphy with transrectally administered 123I-iodoamphetamine (IMP). The shunt index was 0% in patients without liver diseases, 5.3% in acute hepatitis, 5.9% in chronic inactive hepatitis, 11.4% in chronic active hepatitis, 56.6% in compensated liver cirrhosis and 88.1% in decompensated liver cirrhosis. The shunt index was significantly higher in liver cirrhosis, especially decompensated stage. In 5 of 9 patients with acute hepatitis, shunt index was 0%. In 3 of remaining 4 patients with elevated shunt index, shunt index became 0% within 1-2 months. Significant relationship was observed between the shunt index and hepatic function tests such as ChE, albumin, gamma-globulin and ICG-R15. These results suggest that the shunt index is independent of hepatic cell necrosis and reveals the shunted blood flow exactly. Therefore, this technique is useful for evaluating the portosystemic shunt in various liver diseases.     

Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease

BACKGROUND: The main process involved in hepatic osteodystrophy seems to be osteoporosis, but decreased 25-hydroxylation of vitamin D might lead to osteomalacia and secondary hyperparathyroidism. METHODS AND RESULTS: We studied bone mineral density (BMD) by using DEXA-Expert Lunar, biochemical markers of bone turnover and calcium-parathyroid hormone (PTH)-vitamin D axis in 100 patients with chronic viral hepatitis secondary to hepatitis C virus: 49 non-cirrhotic (NCir) and 51 with cirrhosis (Cir) confirmed by liver biopsy and/or clinical and biochemical features. When compared to the age-matched population, 25% of the patients had low BMD at the lumbar spine (LS), 26.2% at Ward's triangle, 15.5% at the femoral neck (FN), and 20.2% at the trochanter. No difference was found either between Cir and NCir groups or between sexes. Urinary N-telopeptide was increased in 31.86% of the patients, and negatively correlated with BMD at the LS and trochanter (P < 0.02). Serum bone-specific alkaline phosphatase was elevated in 21% of the patients and negatively correlated with BMD at the trochanter and Ward's triangle (P < 0.02). Fasting 25-hydroxyvitamin D was low in only three Cir patients, with no difference between the Cir and NCir groups, but it was higher in men (51.8 +/- 16.0 ng/mL) compared to women (40.4 +/- 14.4 ng/mL; P = 0.001). Fasting serum calcium was lower in Cir than NCir patients, P = 0.019. Fasting intact PTH was elevated in 42% of the patients, but the mean serum levels were similar in Cir and NCir groups. CONCLUSION: We found no evidence of vitamin D deficiency, but cannot exclude the participation of PTH in the high bone turnover and bone loss in the population with chronic viral hepatitis.     

胰岛素、胰岛素原对胰岛素抵抗状态下HepG2细胞PAI-1分泌的影响

目的研究胰岛素、胰岛素原对胰岛素抵抗状态下ＨｅｐＧ２细胞ＰＡＩ１分泌的影响。方法选择在合成ＰＡＩ１方面与肝细胞相似的ＨｅｐＧ２细胞，以高浓度胰岛素诱导胰岛素抵抗后，分别用生理浓度的胰岛素、胰岛素原刺激２４小时，以观察胰岛素抵抗状态下ＰＡＩ１活性的变化。结果基础状态下胰岛素抵抗ＨｅｐＧ２细胞与非胰岛素抵抗ＨｅｐＧ２细胞相比，ＰＡＩ１活性差异不明显；胰岛素、胰岛素原刺激后，胰岛素抵抗ＨｅｐＧ２细胞ＰＡＩ１活性明显高于非胰岛素抵抗ＨｅｐＧ２细胞。当培液中同时加入１０－４Ｍ二甲双胍后，胰岛素、胰岛素原介导的ＰＡＩ１过量分泌得到明显抑制。结论在胰岛素抵抗状态下，胰岛素、胰岛素原刺激后ＨｅｐＧ２细胞ＰＡＩ１活性明显增加，而二甲双胍可明显抑制此现象。     

Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation

OBJECTIVE: Osteoporosis is frequently found in patients with cholestatic liver disease (primary biliary cirrhosis/primary sclerosing cholangitis) and chronic viral hepatitis. There is limited information about the long-term effect of liver transplantation (OLT) on bone metabolism. The aim of this study was to investigate the effect of liver transplantation on bone metabolism in patients with cholestatic and viral liver diseases. METHODS: We randomly recruited 193 patients with chronic viral hepatitis or cholestatic liver diseases. Bone density (Z-score) and markers of bone metabolism (intact parathyroid hormone [iPTH], PTH 70-84, osteocalcin, procollagen, telopeptide, and vitamin D) were determined before and at time points (< and > 24 months) post-OLT. RESULTS: Before OLT, bone density (Z-score) was decreased in patients with cholestatic (-1) and viral (-0.4) liver diseases. In both groups bone density continued to decrease in the periods up to and more than 24 months after OLT. In the cholestatic group, bone density decreased significantly compared to pre-OLT (p < 0.05) and to the viral hepatitis group (p < 0,001). Markers of bone metabolism showed that after OLT, bone metabolism was enhanced and shifted versus bone resorption. Immunosuppressive drug therapy (glucocorticoids, cyclosporin, FK 506) directly correlated with increased bone metabolism post-OLT. CONCLUSIONS: Bone loss is a long-term problem after OLT, particularly in patients with cholestatic liver diseases. Drug therapy is a main factor of bone loss. Pre- and post-OLT therapy to reduce bone loss is recommended.     

Knochendichte und 25-OH-Vitamin-D- Serumspiegel bei Patienten mit systemischem Lupus erythematodes

OBJECTIVE: To clarify the influence of vitamin D metabolism on bone mineral density (BMD) or bone metabolism in patients with systemic lupus erythematosus (SLE). METHODS: 57 consecutive patients in our department (mean age 33.9 years, 44 female, 13 male) were studied. BMD was measured with dual-X-ray absorptiometry at the lumbar spine and femoral neck. Biochemical investigation of bone metabolism included measurement of vitamin D metabolites, intact parathyroid hormone (PTH), serum osteocalcin und urinary pyridinoline-crosslink excretion. RESULTS: 25 patients had 25-OH cholecalciferol serum values below the normal range after adjustment for seasonal changes; 9 patients were severely vitamin D depleted with 25-OH vitamin D serum values below 5 ng/ml. Low 25-OH-vitamin D was significantly associated with high disease activity. Mean 1.25 (OH)2-vitamin D, PTH, osteocalcin and crosslink excretion were in the normal range. Thirty-six patients had normal BMD; 5 patients had osteoporosis according to WHO diagnosis criteria. No correlation of biochemical parameters of bone metabolism with BMD was found. CONCLUSION: Severe vitamin D depletion was common in this group of patients with SLE even after adjustment for seasonal variations, especially in patients with high disease activity. Therefore, D-hypovitaminosis should be included in the differential diagnosis in patients with SLE presenting with low bone mass.     

Impairment of bone mass development in children with chronic cholestatic liver disease

OBJECTIVE: To analyse aspects of mineral metabolism, bone mineral density (BMD), bone remodelling activity and serum IGF-1 levels in children with chronic cholestatic disease (CCLD). PATIENTS AND MEASUREMENTS: A total of 13 children with chronic cholestatic liver disease (CCLD; mean age 7.2 +/- 4.8 years) and 22 control subjects (mean age 7.6 +/- 4.5 years) were studied. Serum osteocalcin, bone alkaline phosphatase (BAP), 25-hydroxyvitamin D, PTH and IGF-1 levels and urinary deoxypyridinoline were determined. BMD was measured by dual-energy X-ray absorptiometry in the lumbar spine, total hip and whole body. Lumbar spine areal BMD was converted mathematically to apparent volumetric BMD (aBMD) and corrected for the bone age of the patient. RESULTS: Z-score of lumbar spine BMD was lower in CCLD patients than in controls and the difference was maintained when BMD was expressed as aBMD (control = 0.107 +/- 0.02 vs. CCLD = 0.092 +/- 0.02 g/cm(3), P < 0.05) and after conversion for bone age. All participants showed normal 25-hydroxyvitamin D levels, with no significant differences in serum levels of 25-hydroxyvitamin D and PTH between groups. IGF-1 levels were significantly lower in the CCLD group (control = 19.6 +/- 16.8 vs. CCLD = 6.4 +/- 7.6 nmol/l, P < 0.05) and a positive correlation was observed between whole body BMD and IGF-1 in this group. CONCLUSIONS: These results indicate that CCLD limits bone mass gain in children. A reduction in hepatic IGF-1 production might be responsible, at least in part, for the low bone mass of these patients.     

血清胆碱酯酶与慢性乙型肝炎和肝硬化患者临床及病理的关系

目的 探讨血清胆碱酯酶(ChE)与慢性肝病患者的临床及病理的关系。方法随机选择105例慢性肝病患者，检测血清ChE活性，并行肝组织病理检查。结果肝病程度越重，ChE活性值降低愈明显，两者呈明显的负相关。肝组织炎症活动度及纤维化程度越高，血清ChE活性值降低愈明显，与病理损害程度呈明显的负相关关系。结论血清ChE可用于慢性肝病病情严重程度及预后的判断，血清ChE是观察慢性肝炎患者肝组织炎症及纤维化变化的较敏感指标。     

Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C

BACKGROUND: Non-invasive techniques are being developed to assess the severity of liver disease. Haemodynamic changes in the hepatic circulation during the development of liver disease can be evaluated with contrast-enhanced ultrasound. AIM: To evaluate the possible correlation between ultrasound contrast-agent transit times and different stages of chronic hepatitis C. PATIENTS: Sixteen patients with clinically evident hepatitis C virus-related cirrhosis, 22 non-cirrhotic patients with chronic hepatitis C and 14 controls with no clinical evidence of liver disease were studied. METHODS: Contrast-enhanced hepatic ultrasonography was performed with a sulphur hexafluoride-filled microbubble contrast agent, and time curves of hepatic vein signal intensity were analysed to determine the time of enhancement onset (hepatic vein arrival time) and peak enhancement (hepatic vein peak enhancement). RESULTS: Hepatic vein arrival time in cirrhotic patients was significantly shorter (p<0.001) than in non-cirrhotic patients and controls. Within the group with chronic hepatitis C, METAVIR scores of fibrosis and necro-inflammatory changes had no significant effect on hepatic vein arrival times. CONCLUSION: Analysis of the time of onset of ultrasound contrast enhancement of the hepatic vein appears to be a simple, non-invasive method for reliably excluding cirrhosis with signs of portal hypertension, but not for assessing the severity of either chronic hepatitis C or cirrhosis.     

Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection

BACKGROUND AND AIMS: Vitamin D deficiency is common in patients with small intestinal resection and may lead to secondary hypersecretion of parathyroid hormone (PTH), which in turn may result in increased bone turnover rate and loss of bone mineral. The aims of this study were to investigate the prevalence of vitamin D deficiency, as assessed by low serum concentrations of 25-hydroxyvitamin D (25(OH)D) in patients with small intestinal resection and to explore the relation of 25(OH)D to PTH, markers of bone turnover rate, and bone mineral density (BMD) in these patients. PATIENTS: Forty two patients with small intestinal resection, a faecal energy excretion of more than 2.0 MJ/day, and a mean length of the remaining small intestine of 199 cm were included. Diagnoses were Crohn's disease (n=35) and other (n=7). METHODS: 25(OH)D was analysed by radioimmunoassay and bone turnover rate was assessed by measurement of serum osteocalcin, serum alkaline phosphatase, urine pyridinoline, and urine deoxypyridinoline. BMD was measured by dual energy x ray absorptiometry. RESULTS: Mean 25(OH)D concentration was 13.4 (SD 9.7) ng/ml, which was significantly below the reference mean of 26.4 (SD 13.2) ng/ml (p<0.001). Vitamin D deficiency (25(OH)D concentration 相似文献   

慢性肝病患者髂骨病理变化的观察及意义

对１７例乙肝后肝经和１４例慢性活动性肝炎患者的髂骨病理组织学改变进行了观察,发现肝硬化组骨质疏松的发生率为８２．５３％,肝炎组为３５．７１％,两组比较差异显著。提示随肝脏病变程度加重,其相关骨病的发生率亦之增加。将髂骨病理改变分为三组,为诊断肝性骨病（ＨＢＤ）提供了依据。     

不同性别老年髋部骨折患者骨密度T值及骨代谢状况分析

目的了解不同性别老年髋部骨折患者的骨密度情况及骨折早期骨转换生化标志物的变化特点及差异。方法收集2015年5月至2017年12月北京积水潭医院老年髋部骨折病房住院的1161例患者临床资料、骨密度检查结果以及血清I型前胶原氨基末端前肽(P1NP)、25羟基维生素D3[25-(OH)VD3]、I型胶原交联羧基末端肽β降解产物(β-CTX)、血清骨钙素(OC)、甲状旁腺激素(PTH)等进行回顾性研究。结果共纳入女831例,男330例,其中(1)腰椎及髋部总体骨密度显示:T≥-1.0 SD分别为30.4%(353/1161)、6.8%(79/1161);-2.5 SD相似文献